Clinical Trials Logo

Giant Cell Tumor of Bone clinical trials

View clinical trials related to Giant Cell Tumor of Bone.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05595603 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage

Start date: March 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).

NCT ID: NCT04586660 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Start date: August 17, 2023
Phase: Phase 4
Study type: Interventional

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

NCT ID: NCT03295981 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Start date: May 3, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

NCT ID: NCT03259152 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone

D-Gct
Start date: May 1, 2016
Phase: Phase 3
Study type: Interventional

Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of relapsed or refractoriness GCT with denosumab and to assess adverse effect profile and recurrence rate.